Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2018

01-06-2018 | Original article

Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis

Authors: Kengo Furuichi, Miho Shimizu, Yukio Yuzawa, Akinori Hara, Tadashi Toyama, Hiroshi Kitamura, Yoshiki Suzuki, Hiroshi Sato, Noriko Uesugi, Yoshifumi Ubara, Junichi Hoshino, Satoshi Hisano, Yoshihiko Ueda, Shinichi Nishi, Hitoshi Yokoyama, Tomoya Nishino, Kentaro Kohagura, Daisuke Ogawa, Koki Mise, Yugo Shibagaki, Kenjiro Kimura, Masakazu Haneda, Hirofumi Makino, Seiichi Matsuo, Takashi Wada, Research Group of Diabetic Nephropathy and Nephrosclerosis, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development

Published in: Clinical and Experimental Nephrology | Issue 3/2018

Login to get access

Abstract

Background

Nephrosclerosis is an increasingly reason for dialysis in Japan. However, kidney biopsy specimens for hypertensive nephrosclerosis are very limited; thus, the pathologic evaluation of hypertensive nephrosclerosis currently remains unclear.

Methods

Clinical and pathologic data of a total of 184 biopsy-confirmed hypertensive nephrosclerosis patients were collected from 13 centers throughout Japan. Seven pathological findings were assessed in this study. The outcomes of interest for this study were dialysis, composite kidney events, cardiovascular events, and all-cause mortality.

Results

The Green and Yellow (G&Y), Orange, and Red groups of the chronic kidney diseases (CKD) heat map contained 36, 57, and 91 cases, respectively. The mean observation period was 7.3 ± 5.2 (median, IQR; 6.1, 2.6–9.7) years. Global glomerulosclerosis (GScle), interstitial fibrosis and tubular atrophy (IFTA), arteriolar hyalinosis in Red exhibited higher scores than those in G&Y and Orange. The incidence rates of the composite kidney end points in 100 person-years for the G&Y, Orange, and Red groups were 1.42, 2.16, and 3.98, respectively. In the univariate Cox analysis for the composite kidney end points, GScle, IFTA and interstitial cell infiltration exhibited statistically significant high hazard ratios (1.18, 1.84, 1.69, respectively). However, after adjustment for clinical and medication data, the Red group in the CKD heat map category was risk factor for the composite kidney end points (HR 9.51).

Conclusions

In summary, although pathologic findings had minor impacts on the prediction of composite outcomes in this study, the clinical stage of the CKD heat map is a good predictor of composite kidney events.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanafusa N, Nakai S, Iseki K, et al. Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl. 2015;5(1):15–22.CrossRef Hanafusa N, Nakai S, Iseki K, et al. Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl. 2015;5(1):15–22.CrossRef
2.
go back to reference Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis. 2006;48(5):739–51.CrossRefPubMed Norris K, Bourgoigne J, Gassman J, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis. 2006;48(5):739–51.CrossRefPubMed
3.
go back to reference Vikse BE, Aasarod K, Bostad L, et al. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant. 2003;18(3):517–23.CrossRefPubMed Vikse BE, Aasarod K, Bostad L, et al. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol Dial Transplant. 2003;18(3):517–23.CrossRefPubMed
4.
go back to reference Suzuki H, Kobayashi K, Ishida Y, et al. Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years’ experience in a single, kidney disease center. Ther Adv Cardiovasc Dis. 2015;9(3):77–86.CrossRefPubMed Suzuki H, Kobayashi K, Ishida Y, et al. Patients with biopsy-proven nephrosclerosis and moderately impaired renal function have a higher risk for cardiovascular disease: 15 years’ experience in a single, kidney disease center. Ther Adv Cardiovasc Dis. 2015;9(3):77–86.CrossRefPubMed
5.
go back to reference Takebayashi S, Kiyoshi Y, Hisano S, et al. Benign nephrosclerosis: incidence, morphology and prognosis. Clin Nephrol. 2001;55(5):349–56.PubMed Takebayashi S, Kiyoshi Y, Hisano S, et al. Benign nephrosclerosis: incidence, morphology and prognosis. Clin Nephrol. 2001;55(5):349–56.PubMed
6.
go back to reference Dasgupta I, Porter C, Innes A, et al. “Benign” hypertensive nephrosclerosis. QJM. 2007;100(2):113–9.CrossRefPubMed Dasgupta I, Porter C, Innes A, et al. “Benign” hypertensive nephrosclerosis. QJM. 2007;100(2):113–9.CrossRefPubMed
7.
go back to reference Liang S, Le W, Liang D, et al. Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. BMC Nephrol. 2016;17:42.CrossRefPubMedPubMedCentral Liang S, Le W, Liang D, et al. Clinico-pathological characteristics and outcomes of patients with biopsy-proven hypertensive nephrosclerosis: a retrospective cohort study. BMC Nephrol. 2016;17:42.CrossRefPubMedPubMedCentral
8.
go back to reference Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61.CrossRefPubMed Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61.CrossRefPubMed
9.
go back to reference Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis. 2015;65(2):177–205.CrossRefPubMed Akbari A, Clase CM, Acott P, et al. Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. Am J Kidney Dis. 2015;65(2):177–205.CrossRefPubMed
11.
go back to reference Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.CrossRefPubMed
12.
go back to reference Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.CrossRefPubMed Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17–28.CrossRefPubMed
13.
go back to reference Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol. 2006;17(10):2928–36.CrossRefPubMed Norris KC, Greene T, Kopple J, et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol. 2006;17(10):2928–36.CrossRefPubMed
14.
go back to reference Sumida K, Hoshino J, Ueno T, et al. Effect of proteinuria and glomerular filtration rate on renal outcome in patients with biopsy-proven benign nephrosclerosis. PLoS One. 2016;11(1):e0147690.CrossRefPubMedPubMedCentral Sumida K, Hoshino J, Ueno T, et al. Effect of proteinuria and glomerular filtration rate on renal outcome in patients with biopsy-proven benign nephrosclerosis. PLoS One. 2016;11(1):e0147690.CrossRefPubMedPubMedCentral
15.
go back to reference Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997;51(1):244–52.CrossRefPubMed Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997;51(1):244–52.CrossRefPubMed
16.
go back to reference Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168(8):832–9.CrossRefPubMed Appel LJ, Wright JT Jr, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168(8):832–9.CrossRefPubMed
17.
Metadata
Title
Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis
Authors
Kengo Furuichi
Miho Shimizu
Yukio Yuzawa
Akinori Hara
Tadashi Toyama
Hiroshi Kitamura
Yoshiki Suzuki
Hiroshi Sato
Noriko Uesugi
Yoshifumi Ubara
Junichi Hoshino
Satoshi Hisano
Yoshihiko Ueda
Shinichi Nishi
Hitoshi Yokoyama
Tomoya Nishino
Kentaro Kohagura
Daisuke Ogawa
Koki Mise
Yugo Shibagaki
Kenjiro Kimura
Masakazu Haneda
Hirofumi Makino
Seiichi Matsuo
Takashi Wada
Research Group of Diabetic Nephropathy and Nephrosclerosis, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development
Publication date
01-06-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 3/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1496-4

Other articles of this Issue 3/2018

Clinical and Experimental Nephrology 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine